Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Drug Discov Devel. 2007 Sep;10(5):533-9.

Peptide inhibitors of beta-amyloid aggregation.

Author information

  • 1Faculty of Life Sciences, Manchester Interdisciplinary Biocentre, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.


The aggregation of the beta-amyloid peptide (Abeta) into toxic oligomers is probably the key pathogenic event in the onset of Alzheimer's disease, and is therefore a target for the treatment of the disease. A plethora of organic molecules have been shown to inhibit Abeta aggregation and toxicity. Many inhibitors are peptides or peptidomimetics, typically based on the amino acids 16 to 20 of Abeta (KLVFF), which binds to Abeta in isolation. Peptides have been modified by adding bulky groups, charged sequences or polyethylene glycol to their termini, or by N-methylation, replacing a backbone amide by an ester, and by replacing a residue with proline.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk